Drug intelligence / Profile preview

GAM501

Development stage
Phase 2
Lead developer
Tissue Repair Company
Modality
Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration
Topical
01

Overview

**GAM501** is an investigational topical gene therapy formerly developed as **Excellarate** for chronic non-healing diabetic foot ulcers. It consists of a replication-defective adenovirus serotype 5 vector encoding human platelet-derived growth factor subunit B, formulated in a bovine type I collagen gel that acts as a local wound matrix. Local expression of platelet-derived growth factor-B is intended to stimulate platelet-derived growth factor receptor signaling, promoting recruitment and proliferation of fibroblasts and other reparative cells, angiogenesis, granulation tissue formation, and wound closure. GAM501 was evaluated in completed Phase 1/2 and Phase 2b clinical studies in neuropathic diabetic foot ulcers.

Brand names
Excellarate
Other names
Ad5PDGF-B/bovine type I collagen gelExcellarate
02

Targets

PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)

Beyond the preview

Go deeper on GAM501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on GAM501.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call